Eric Swayze Sells 1,367 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 1,367 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $32.31, for a total value of $44,167.77. Following the sale, the executive vice president now owns 48,017 shares of the company’s stock, valued at $1,551,429.27. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Eric Swayze also recently made the following trade(s):

• On Thursday, January 16th, Eric Swayze sold 7,154 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $32.84, for a total value of $234,937.36.
• On Tuesday, November 12th, Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48.

Ionis Pharmaceuticals Stock Up 0.7 %

Ionis Pharmaceuticals stock traded up $0.23 during mid-day trading on Monday, hitting $32.13. The company had a trading volume of 1,662,595 shares, compared to its average volume of 1,661,709. The business has a fifty day moving average of $35.07 and a 200 day moving average of $40.00. Ionis Pharmaceuticals, Inc. has a 1 year low of $31.03 and a 1 year high of $52.34. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of -13.17 and a beta of 0.35.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on IONS shares. William Blair reiterated an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Piper Sandler dropped their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. StockNews.com downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday, January 15th. Finally, Wells Fargo & Company decreased their price target on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $60.65.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in shares of Ionis Pharmaceuticals by 7.4% in the third quarter. Geode Capital Management LLC now owns 2,668,358 shares of the company’s stock valued at $106,922,000 after buying an additional 183,814 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Ionis Pharmaceuticals by 8.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,443,020 shares of the company’s stock worth $57,807,000 after purchasing an additional 114,914 shares during the last quarter. ARK Investment Management LLC lifted its position in Ionis Pharmaceuticals by 1.7% during the third quarter. ARK Investment Management LLC now owns 1,384,269 shares of the company’s stock worth $55,454,000 after buying an additional 23,244 shares during the period. Two Sigma Advisers LP grew its stake in shares of Ionis Pharmaceuticals by 3.5% during the 3rd quarter. Two Sigma Advisers LP now owns 1,332,411 shares of the company’s stock valued at $53,376,000 after buying an additional 45,300 shares during the period. Finally, Groupama Asset Managment raised its holdings in Ionis Pharmaceuticals by 4.1% in the third quarter. Groupama Asset Managment now owns 916,060 shares of the company’s stock valued at $367,000 after buying an additional 36,084 shares during the period. 93.86% of the stock is owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.